Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after Cisplatin-containing therapy: a Japanese experience.

@article{Akaza2007EfficacyAS,
  title={Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after Cisplatin-containing therapy: a Japanese experience.},
  author={Hideyuki Akaza and Seiji Naito and Michiyuki Usami and Tsuneharu Miki and Naoto Miyanaga and Hisashi Taniai},
  journal={Japanese journal of clinical oncology},
  year={2007},
  volume={37 3},
  pages={201-6}
}
BACKGROUND In Japan, the standard chemotherapy for advanced transitional cell carcinoma (TCC) of the urothelium is MVAC (methotrexate, vinblastine, adriamycin, cisplatin). However, a second-line therapy is still required for patients with recurrent TCC who discontinued MVAC because of toxicity or have MVAC refractory tumors. METHODS We evaluated gemcitabine monotherapy in patients with advanced TCC who were previously treated with a platinum-based regimen. Gemcitabine (1000 mg/m2) was given… CONTINUE READING
9 Citations
26 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Cancer of the bladder, ureter, and renal pelvis

  • WU Shipley, DS Kaufman, WS McDougal, DM Dahl, MD Michaelson, AL. Zeitman
  • Cancer: Jpn J Clin Oncol 2007;37(3)
  • 2004

Non-small-cell lung cancer a) Internal medicine

  • N. Yamamoto
  • Tokyo: Cancer and Chemotherapy Publishers
  • 2003

Transitional cell carcinoma of the urothelium

  • T Torii, H. Akaza
  • Tokyo: Cancer and Chemotherapy Publishers
  • 2003

Similar Papers

Loading similar papers…